您当前的位置：

ABR-238901

目录号: PL12347 纯度: ≥99%

ABR-238901 是一种口服有效的 S100A8/A9 阻滞剂，可抑制 S100A8/A9 与其受体 RAGE (晚期糖基化终产物受体) 和 TLR4(toll 样受体 4）的相互作用。ABR-238901 具有用于心肌梗塞 (MI) 研究的潜力。

CAS No. :1638200-22-2

商品编号	规格	价格	会员价
PL12347-5mg	5mg	¥2645.00	请登录
PL12347-10mg	10mg	¥3925.00	请登录
PL12347-50mg	50mg	¥8625.00	请登录
PL12347-100mg	100mg	¥11595.00	请登录
PL12347-10mM*1mLinDMSO	10mM*1mLinDMSO	¥6718.00	请登录
PL12347-1 mL x 10 mM (in DMSO)		¥2295.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	ABR-238901
英文名称	ABR-238901
英文别名	3-Pyridinesulfonamide, 5-bromo-N-(5-chloro-4-hydroxy-3-pyridinyl)-6-methoxy-;ABR-238901
Cas No.	1638200-22-2
分子式	C₁₁H₉BrClN₃O₄S
分子量	394.63
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	ABR-238901 是一种口服有效的 S100A8/A9 阻滞剂，可抑制 S100A8/A9 与其受体 RAGE (晚期糖基化终产物受体) 和 TLR4(toll 样受体 4）的相互作用。ABR-238901 具有用于心肌梗塞 (MI) 研究的潜力。

产品详情	ABR-238901 是一种口服有效的 S100A8/A9 阻滞剂，可抑制 S100A8/A9 与其受体 RAGE (晚期糖基化终产物受体) 和 TLR4(toll 样受体 4）的相互作用。ABR-238901 具有用于心肌梗塞 (MI) 研究的潜力。
生物活性	ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.
性状	Solid
体内研究(In Vivo)	ABR-238901 (30 mg/kg/day; gavage; for 3 weeks) causes less angiogenesis and less IL6 and IL10 in MDSCs. ABR-238901 (30 mg/kg/day; gavage) in combination with Bortezomib (0.6 mg/kg; sc; 2 times/week) reduces tumor load compared with treatments of either agent alone. ABR-238901 (30 mg/kg; IP for the first 3 d and thereafter continuously p.o.; daily; for 21 days) leads to gradual deterioration of cardiac function and accelerated left ventricular remodeling in C57BL/6NRJ mice with myocardial ischemia induced by permanent coronary artery ligation. Treatment with ABR-238901 during the first 3 days post-myocardial infarction (MI) restricts the inflammatory damage and promotes a reparatory environment. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846. [2]. Goran Marinkovi?, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127(5):664-676.

溶解度数据	In Vitro: DMSO : 33.33 mg/mL (84.46 mM; ultrasonic and warming and heat to 60°C)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5(10):839-846.
[2]. Goran Marinkovi?, et al. S100A9 Links Inflammation and Repair in Myocardial Infarction. Circ Res. 2020 Aug 14;127(5):664-676.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

ABR-238901

相关产品

The molarity calculator equation

The dilution calculator equation